Dr. Calum MacRae, chief of cardiovascular medicine at Brigham and Women’s Hospital in Boston, and his world-class team were selected as the recipients of the One Brave Idea research award.
On October 5, 2016, the American Heart Association, Verily Life Sciences LLC and AstraZeneca announced Dr. Calum MacRae as the leader of our One Brave Idea initiative. He beat out hundreds of other applicants from around the world to receive this landmark award that will provide support over a five-year period for a research project focused on uncovering the causes of heart disease, including previously unrecognized signals marking the transition from wellness to the earliest, yet still largely invisible stages of disease.
Dr. Calum MacRae is a cardiologist, geneticist and developmental biologist who graduated from Edinburgh and London before coming to Boston in 1991. After postdoctoral fellowships in human genetics with Drs. Christine and Jon Seidman and developmental biology with Dr. Mark Fishman, as well as additional clinical training in internal medicine and cardiology, he joined the Division of Cardiology at Massachusetts General Hospital in 2001. His research is focused on understanding the genetic contribution to common cardiovascular disease using human studies and complementary high-throughput biology in the zebrafish.
Dr. MacRae is also the Chief of Cardiology at the Brigham and Women’s Hospital. His clinical interests include the management of inherited heart disease and cardiac involvement in systemic diseases.
In addition, Dr. MacRae is a leading investigator at the Brigham and Women’s Hospital Genomics Center, a principal faculty member at the Cardiovascular Research Center and the Harvard Stem Cell Institute, and an associated member at the Broad Institute.
Led by Calum MacRae, chief of cardiovascular medicine at Brigham and Women’s Hospital (BWH), the One Brave idea team is comprised of a team of investigators from a wide variety of specialties like engineering and data scientists and institutions including MIT and Stanford. Each has experience breaking down boundaries and working outside the constraints of traditional biomedical science.
The team will work out of The One Brave Idea Science Innovation Center in Boston to facilitate new techniques in a clinical context. Here they will have access to a national consortium of translational scientists, engineering expertise of MIT and the clinical device expertise of BWH’s Next Generation Phenotyping Center.
Stanley Shaw, MD PhD is the Chief Scientific Officer (CSO) for the One Brave Idea initiative, Associate Dean for Executive Education at Harvard Medical School, and an Associate Member of the Broad Institute of Harvard and MIT. His research has sought to develop new phenotypes (measurable traits) for the assessment of human wellness and disease, through the study of patient-derived cells, Electronic Health Records (EHR), the gut microbiome and digital health. His team led the development of one of the first ResearchKit apps (for type 2 diabetes) in partnership with Apple. Previously, Dr. Shaw was co-founder and co-director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital (MGH), and a founding Principal Investigator in the MGH Center for Systems Biology. He is a board-certified cardiologist.
Euan Ashley is Associate Professor of Medicine, Genetics and Biomedical Data Science at Stanford University. He is director of the Center for Inherited Cardiovascular Disease, the Clinical Genomics service and the Stanford Data Science Initiative. In 2010, he led the team that carried out the first clinical interpretation of a human genome. He also leads the MyHeart Counts team that collects cardiovascular risk data through an iPhone app. He is co-founder of Personalis and DeepCell.
Dr. Barabasi is both the Robert Gray Dodge Professor of Network Science and a Distinguished University Professor at Northeastern University, where he directs the Center for Complex Network Research, and holds appointments in the Departments of Physics and Computer Science, as well as in the Department of Medicine, Harvard Medical School and Brigham and Women Hospital, and is a member of the Center for Cancer Systems Biology at Dana Farber Cancer Institute. Barabasi’s latest book is “Bursts: The Hidden Pattern Behind Everything We Do” (Dutton, 2010) available in five languages. He has also authored “Linked: The New Science of Networks” (Perseus, 2002), currently available in eleven languages, and is the co-editor of “The Structure and Dynamics of Networks” (Princeton, 2005). His work lead to the discovery of scale-free networks in 1999, and proposed the Barabasi-Albert model to explain their widespread emergence in natural, technological and social systems, from the cellular telephone to the WWW or online communities.
Barabasi is a Fellow of the American Physical Society. In 2005 he was awarded the FEBS Anniversary Prize for Systems Biology and in 2006 the John von Neumann Medal by the John von Neumann Computer Society from Hungary, for outstanding achievements in computer-related science and technology. In 2004 he was elected into the Hungarian Academy of Sciences and in 2007 into the Academia Europaea. He received the C&C Prize from the NEC C&C Foundation in 2008. In 2009 APS chose him Outstanding Referee and the US National Academies of Sciences awarded him the 2009 Cozzarelli Prize. In 2011 Barabasi was awarded the Lagrange Prize-CRT Foundation for his contributions to complex systems, awarded Doctor Honoris Causa from Universidad PolitŽcnica de Madrid, became an elected Fellow in AAAS (Physics) and is a 2013 Fellow of the Massachusetts Academy of Sciences.
Dr. Edelman, MIT Cabot Professor of Health Sciences and Technology, and Harvard Medical School Professor of Medicine, is a cardiac care unit cardiologist at Brigham and Women’s Hospital and director of MIT’s Biomedical Engineering Center. His research melds clinical and medical training, focusing on how tissue architecture and local biochemical regulation maintain homeostasis. Edelman and his students were amongst the first to validate that vascular diseases are the sum of effects from endogenous growth promoters like heparin and suppressors like heparin-binding growth factors, to define the nomenclature and kinetics of the FGF-2 receptor complex, and demonstrate that mode of growth factor or inhibitor delivery determines biologic effect. Edelman is fellow of the American College of Cardiology, American Heart Association, American Institute for Medical and Biological Engineering, American Society for Clinical Investigation, American Academy of Arts and Sciences, National Academy of Medicine, National Academy of Engineering and National Academy of Inventors. As Chief Scientific Advisor of Science: Translational Medicine and member of the FDA Scientific Board he has set the tone for the national debate on translational research and innovation.
Dr. Gaziano is a preventive cardiologist and internationally recognized chronic disease epidemiologist whose research interests include the epidemiology of chronic diseases using large data sources. He has a particular interest in the lifestyle, metabolic, biochemical and genetic determinants of common chronic disease such as cardiovascular disease and cancer.
A centerpiece of his research involves the conduct of observational studies and trials that are imbedded in a health care system and the curation of electronic health data from many sources. He serves as one of two PIs of the Million Veteran Program (MVP), a project that will enroll one million veterans into a longitudinal cohort with stored biospecimens, self-reported data and the rich electronic clinical and administrative data available in the VA. To date over 590,000 veterans have been enrolled into MVP. He is principal investigator of the Physicians’ Health Study, a large-scale trial-based cohort of over 29,000 physicians followed for over 30 years. He has also served as PI, Co-PI or co-investigator on a number of other cohort studies and large-scale trials. He serves on advisory committees for the Precision Medicine Initiative and the UKBiobank.
Dr. Gaziano oversees several fellowship programs and teaches advanced epidemiology at the Harvard School of Public Health. He has published over 550 journal articles, reviews, book chapters and books. He has also served as an Associate Editor for the Journal of the American Medical Association. He is a Fellow of the Royal College of Physicians.
Dr. David Grayzel is co-founder and Chairman of the Board of Directors and is a Partner at Atlas Venture. Since joining Atlas Venture in 2010, Dr. Grayzel co-founded and served as chief executive officer of Arteaus Therapeutics, LLC which was acquired by Eli Lilly in 2014, as well as co-founder and CEO of Annovation Biopharma Inc. which was acquired by The Medicines Company in early 2015. He is currently a co-founder and acting CEO of Ataxion, co-founder of Quartet Medicine, and co-founder and executive chairman of Surface Oncology. Previously, he was a member of the executive team at Infinity Pharmaceuticals (NASDAQ: INFI) and was responsible for all clinical research activities as the head of clinical development and medical affairs.
Dr. Grayzel obtained his BA from Stanford University, his MD from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital.
Dr. Huffman is an associate professor of preventive medicine and medicine-cardiology at Northwestern University’s Feinberg School of Medicine. He’s a practicing cardiologist, researcher, and teacher interested in global cardiovascular epidemiology, prevention, and implementation science research and research training. In 2017, he completed an acute coronary syndrome quality improvement clinical trial including >21,000 participants across 63 sites in Kerala, India funded by a NHLBI K99/R00 award with the Cardiological Society of India – Kerala and Centre for Chronic Disease Control. Huffman has served as the senior program advisor to the World Heart Federation for its Emerging Leaders program, which has trained 100 individuals from 42 countries over the past 4 years to help achieve the WHO’s goal of reducing premature mortality from noncommunicable diseases, including heart diseases and stroke, by 25% by 2025. He is also an associate editor for JAMA Cardiology and former coordinating editor of the Cochrane Heart Group US Satellite where he led evidence synthesis and open data projects related to polypills, statins, risk scores, atrial fibrillation surgery, electrophysiological catheters, and implantable defibrillators. In addition, Huffman also serves as co-director for Northwestern’s cardiology fellowship research training program (population health) and Northwestern’s Fogarty-funded global health training program as part of the Harvard University, Boston University, Northwestern University, University of Mexico (HBNU) consortium.
Dr. Christopher O’Donnell is a physician-investigator who is committed to translating population science discoveries to the prevention and treatment of cardiovascular, metabolic, and other chronic diseases, to enhance the health and quality of life of patients, families and populations. He has two decades of executive leadership experience directing successful collaborative, interdisciplinary clinical and population research programs; founding and leading international multi-institution consortia and research networks; and steering strategy for large genomics programs at the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH) and Veteran’s Administration (VA) Healthcare System.
As Chief of Cardiology and Director for the Center for Population Genomics, of Boston VA, he oversees a robust clinical, teaching and research program for the Cardiology Section that includes over 75 full-time and part-time staff and serves as the main tertiary care referral center for the VA New England Healthcare System. He serves as Chief Scientist of the national VA Million Veteran Program. He is VA Principal Investigator and serves on the Executive Committee of the NIH Precision Medicine Initiative All of Us Cohort Program. He is author on >550 peer-reviewed articles and chapters, including reports in high impact journals such as NEJM, JAMA, and Nature Genetics and is listed as the top 1% most cited for both Clinical Medicine and Molecular Biology/Genetics on the 2015 Thomson Reuters Highly Cited Researchers list.
Frederick (Fritz) Roth trained in physics and biology at UC Berkeley, in biophysics at Harvard, and in industry at Millennium Pharmaceuticals. His research team—ten years at Harvard Medical School and at the University of Toronto’s Donnelly Centre and Mt. Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute since 2011—develops computational and experimental technology to identify disease-associated mutations and map functional relationships of disease-relevant genes. Current projects include large-scale mapping of interactions among yeast and human proteins, and on exhaustive mutagenesis and functional testing to experimentally characterize functional human DNA sequence variation.
Vasan is a cardiologist with subspecialty training in echocardiography and cardiovascular epidemiology, and has a long-standing commitment to clinical epidemiological research. He has worked at the Framingham Study as a senior investigator for 17 years and is currently the Principal Investigator for the entire study. Presently, Vasan is the Editor of Circulation Cardiovascular Genetics and Associate Editor of Circulation. He is the Chief in the Section of Preventive Medicine and Epidemiology in the Department of Medicine and Professor of Medicine at Boston University School of Medicine.
Joint Leadership Group
One Brave Idea is governed by a Joint Leadership Group comprised of the funding organizations – American Heart Association, Verily and AstraZeneca. An important business goal of One Brave Idea is to create an evergreen pooled Research Fund with selected partners to drive shared value, and to create a long term positive impact within society globally as we strive to create a healthier future for all.